Document Detail


Ropivacaine: a pharmacological review.
MedLine Citation:
PMID:  15853505     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ropivacaine (Naropin, AstraZeneca) a new long-acting amide local anaesthetic agent, is a pure S-enantiomer, with a high pKa and relatively low-lipid solubility. Since its clinical introduction in 1996, it has been the focus of intense interest because of its increased CNS and cardiovascular safety compared with bupivacaine. This article reviews the pharmacology of ropivacaine with particular emphasis placed on toxicological issues. Compared with bupivacaine (the drug of choice for many years), ropivacaine is equally effective for subcutaneous infiltration, epidural, intrathecal and peripheral nerve block surgery, and obstetrics and postoperative analgesia. Ropivacaine is virtually identical to bupivacaine in terms of onset, quality and duration of sensory block, but seems to produce less motor block. The lesser toxicity of ropivacaine compared with bupivacaine has been confirmed in numerous animal experiments as well as human studies, including studies considering the presumed lower potency of ropivacaine. In fact, the reduced cardiovascular toxicity compared with bupivacaine may be a distinct feature of ropivacaine. So far, the increased cost of ropivacaine compared with bupivacaine has limited its wider clinical use -- in spite of the improved safety profile. During the last few years, cost differences between bupivacaine and ropivacaine have been minimized, thus making pharmacoeconomical speculations a much lesser concern when choosing a local anaesthetic drug. In conclusion, ropivacaine appears to be a safer local anaesthetic agent than bupivacaine. It seems particularly indicated for major peripheral nerve blocks and obstetrics. Ropivacaine should be considered when regional blocks are used in neonates and young infants. With the current trend in the cost development, ropivacaine will most likely be used increasingly in the future.
Authors:
Tom G Hansen
Related Documents :
7956885 - Seizures in pregnancy.
7062285 - Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mo...
902675 - Recording of drug prescriptions in the county of jämtland, sweden. ii. drug exposure of...
21693025 - Individualised controlled ovarian stimulation (icos): maximising success rates for assi...
22742605 - The effects of iodine deficiency in pregnancy and infancy.
12453085 - Septo-optic dysplasia with digital anomalies associated with maternal multidrug abuse d...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of neurotherapeutics     Volume:  4     ISSN:  1744-8360     ISO Abbreviation:  Expert Rev Neurother     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2005-04-27     Completed Date:  2006-04-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101129944     Medline TA:  Expert Rev Neurother     Country:  England    
Other Details:
Languages:  eng     Pagination:  781-91     Citation Subset:  IM    
Affiliation:
Department of Anaesthesia & Intensive Care, Odense University Hospital, DK-5000 Odense C, Denmark. tomghansen@dadlnet.dk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amides / chemistry,  metabolism,  pharmacology*
Anesthetics, Local / chemistry,  metabolism,  pharmacology*
Animals
Clinical Trials, Phase I as Topic
Drug Tolerance
Economics, Pharmaceutical
Humans
Models, Animal
Chemical
Reg. No./Substance:
0/Amides; 0/Anesthetics, Local; 84057-95-4/ropivacaine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Escitalopram: better treatment for depression is through the looking glass.
Next Document:  Inflammatory processes and Alzheimer's disease.